ES2197818B1 - 2,7,12,17 alquenil, aril y heteroaril derivados del 3,6,13,16-tetraazaporficeno, y procedimiento, compuesto intermedio y utilizaciones correspondientes. - Google Patents

2,7,12,17 alquenil, aril y heteroaril derivados del 3,6,13,16-tetraazaporficeno, y procedimiento, compuesto intermedio y utilizaciones correspondientes.

Info

Publication number
ES2197818B1
ES2197818B1 ES200201331A ES200201331A ES2197818B1 ES 2197818 B1 ES2197818 B1 ES 2197818B1 ES 200201331 A ES200201331 A ES 200201331A ES 200201331 A ES200201331 A ES 200201331A ES 2197818 B1 ES2197818 B1 ES 2197818B1
Authority
ES
Spain
Prior art keywords
intermediate compound
tetraazaporficeno
alquenil
heteroaril
aril
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200201331A
Other languages
English (en)
Other versions
ES2197818A1 (es
Inventor
Jose Ignacio Borell Bilbao
Salvador Borros Gomez
Carles Colominas Guardia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Quimic de Sarria CETS Fundacio Privada
Original Assignee
Institut Quimic de Sarria CETS Fundacio Privada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Quimic de Sarria CETS Fundacio Privada filed Critical Institut Quimic de Sarria CETS Fundacio Privada
Priority to ES200201331A priority Critical patent/ES2197818B1/es
Priority to PCT/ES2003/000267 priority patent/WO2003104237A1/es
Priority to AU2003232859A priority patent/AU2003232859A1/en
Publication of ES2197818A1 publication Critical patent/ES2197818A1/es
Application granted granted Critical
Publication of ES2197818B1 publication Critical patent/ES2197818B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

2,7,12,17 Alquenil, aril y heteroaril derivados del 3,6,13,16- tetraazaporficeno, y procedimiento, compuesto intermedio y utilizaciones correspondientes. La presente invención desarrolla la síntesis de sistemas 3,6,13,16-tetraazaporficénicos de fórmula general (1) donde R puede ser un grupo alquenilo (vinilo o estirilo), o un grupo arilo el cual puede estar no sustituido o sustituido por uno o varios grupos alquilo C1-6, alcoxilo C1-6, amino, mono- o dialquilamino o hidroxicarbonilo, o un grupo heteroarilo (tienilo o piridilo) el cual puede estar no sustituido o sustituido por uno o más grupos alquilo C1-6.
ES200201331A 2002-06-11 2002-06-11 2,7,12,17 alquenil, aril y heteroaril derivados del 3,6,13,16-tetraazaporficeno, y procedimiento, compuesto intermedio y utilizaciones correspondientes. Expired - Fee Related ES2197818B1 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ES200201331A ES2197818B1 (es) 2002-06-11 2002-06-11 2,7,12,17 alquenil, aril y heteroaril derivados del 3,6,13,16-tetraazaporficeno, y procedimiento, compuesto intermedio y utilizaciones correspondientes.
PCT/ES2003/000267 WO2003104237A1 (es) 2002-06-11 2003-06-03 2,7,12,17 alquenil, aril y heteroaril derivados del 3,6,13,16-tetraazaporficeno, y procedimiento, compuesto intermedio y utilizaciones correspondientes
AU2003232859A AU2003232859A1 (en) 2002-06-11 2003-06-03 2,7,12,17 alkenyl, aryl and heteroaryl derived from 3,6,13,16-tetraazaporphycene, method, intermediate compound and corresponding utilizations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200201331A ES2197818B1 (es) 2002-06-11 2002-06-11 2,7,12,17 alquenil, aril y heteroaril derivados del 3,6,13,16-tetraazaporficeno, y procedimiento, compuesto intermedio y utilizaciones correspondientes.

Publications (2)

Publication Number Publication Date
ES2197818A1 ES2197818A1 (es) 2004-01-01
ES2197818B1 true ES2197818B1 (es) 2005-02-01

Family

ID=29724722

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200201331A Expired - Fee Related ES2197818B1 (es) 2002-06-11 2002-06-11 2,7,12,17 alquenil, aril y heteroaril derivados del 3,6,13,16-tetraazaporficeno, y procedimiento, compuesto intermedio y utilizaciones correspondientes.

Country Status (3)

Country Link
AU (1) AU2003232859A1 (es)
ES (1) ES2197818B1 (es)
WO (1) WO2003104237A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2275416B1 (es) * 2005-07-15 2008-06-01 Institut Quimic De Sarria Cets Derivados halogenados de 4h,5h-tieno (3,2-b: 4,5-b') dipirroles y procedimiento y utilizaciones correspondientes.
DE502005009802D1 (de) 2005-11-10 2010-08-05 Novaled Ag Dotiertes organisches Halbleitermaterial
US7919010B2 (en) 2005-12-22 2011-04-05 Novaled Ag Doped organic semiconductor material
EP1837927A1 (de) 2006-03-22 2007-09-26 Novaled AG Verwendung von heterocyclischen Radikalen zur Dotierung von organischen Halbleitern
ATE394800T1 (de) 2006-03-21 2008-05-15 Novaled Ag Heterocyclisches radikal oder diradikal, deren dimere, oligomere, polymere, dispiroverbindungen und polycyclen, deren verwendung, organisches halbleitendes material sowie elektronisches bauelement
DE102007012794B3 (de) 2007-03-16 2008-06-19 Novaled Ag Pyrido[3,2-h]chinazoline und/oder deren 5,6-Dihydroderivate, deren Herstellungsverfahren und diese enthaltendes dotiertes organisches Halbleitermaterial
DE102007018456B4 (de) 2007-04-19 2022-02-24 Novaled Gmbh Verwendung von Hauptgruppenelementhalogeniden und/oder -pseudohalogeniden, organisches halbleitendes Matrixmaterial, elektronische und optoelektronische Bauelemente
EP1988587B1 (de) 2007-04-30 2016-12-07 Novaled GmbH Oxokohlenstoff-, Pseudooxokohlenstoff- und Radialenverbindungen sowie deren Verwendung
EP1990847B1 (de) 2007-05-10 2018-06-20 Novaled GmbH Verwendung von chinoiden Bisimidazolen und deren Derivaten als Dotand zur Dotierung eines organischen halbleitenden Matrixmaterials
DE102007031220B4 (de) 2007-07-04 2022-04-28 Novaled Gmbh Chinoide Verbindungen und deren Verwendung in halbleitenden Matrixmaterialien, elektronischen und optoelektronischen Bauelementen
US8057712B2 (en) 2008-04-29 2011-11-15 Novaled Ag Radialene compounds and their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244671A (en) * 1991-01-29 1993-09-14 Cytopharm, Inc. Derivatives of porphycene for photodynamic therapy of cancer
US5179120A (en) * 1991-06-28 1993-01-12 Cytopharm, Inc. Porphycene compounds for photodynamic therapy
CA2448570A1 (en) * 2001-05-31 2002-12-05 Miravant Pharmaceuticals, Inc. Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and mri diagnosis

Also Published As

Publication number Publication date
WO2003104237A1 (es) 2003-12-18
AU2003232859A1 (en) 2003-12-22
ES2197818A1 (es) 2004-01-01

Similar Documents

Publication Publication Date Title
ES2197818B1 (es) 2,7,12,17 alquenil, aril y heteroaril derivados del 3,6,13,16-tetraazaporficeno, y procedimiento, compuesto intermedio y utilizaciones correspondientes.
DE60234510D1 (de) 1h-indazolverbindungen die jnk hemmen
CY1115302T1 (el) Ενωση οξαζολιου και φαρμακευτικη συνθεση
MXPA04001016A (es) Derivados de sulfonamida como inhibidores de la gamma secretasa.
HRP20070132T3 (en) Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
BR0210030A (pt) Derivado de fenilpiridinacarbonilpiperazina
NO20052887L (no) Pyridazinonderivater som GSK-3Beta inhibitorer.
ATE522525T1 (de) Arylsubstituierte pyrazolamidverbindungen, die als kinase-inhibitoren von nutzen sind
DE69839735D1 (de) Pyrimidin-5-carboxamid-derivate
KR960704919A (ko) 신규인 펩티드 유도체 (novel peptide derivative)
WO2009109991A3 (en) Novel hydrazide containing tyrosine kinase inhibitors
CO5611195A2 (es) Novedosos inhibidores de la gamma secretasa
ATE503746T1 (de) Neue imidazolidinderivate
TW200519538A (en) Resist compound and radiation-sensitive composition
ATE316531T1 (de) Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1
NO20061045L (no) Imidazolderivater
GT200300284A (es) Derivados de 3h-quinazolin-4-ona
CO5700777A2 (es) Derivados de 4-(2-fenilsulfanil-fenil)-1,2,3,6-tetrahidropiridina como inhibidores de la recaptacion de serotonina
DK1706414T3 (da) Fremgangsmåde til fluorcytidinderivater
MY141784A (en) Phenylpyridylpiperazine compounds
AR039172A1 (es) Derivados de morfolina, antagonistas de ccr3.
DE602006005349D1 (de) Verfahren zur herstellung von hydrazon-derivaten
CY1109716T1 (el) Παραγωγα ετεροαρυλ-αλκυλοκαρβονικων αλατων, η προετοιμασια τους και η εφαρμογη τους ως αναστολεις του ενζυμου faah
BR0308935A (pt) Inibidor de fosfodiesterase iv contendo derivado de piridilacrilamida
SE0402734D0 (sv) Antimiicrobial compounds

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20040101

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2197818B1

Country of ref document: ES

FD1A Patent lapsed

Effective date: 20100315